JP2020514282A - 新規カンナビノイド組成物および使用方法 - Google Patents

新規カンナビノイド組成物および使用方法 Download PDF

Info

Publication number
JP2020514282A
JP2020514282A JP2019534858A JP2019534858A JP2020514282A JP 2020514282 A JP2020514282 A JP 2020514282A JP 2019534858 A JP2019534858 A JP 2019534858A JP 2019534858 A JP2019534858 A JP 2019534858A JP 2020514282 A JP2020514282 A JP 2020514282A
Authority
JP
Japan
Prior art keywords
cbd
composition
day
thc
administered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019534858A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514282A5 (https=
Inventor
ジェイコブソン キャサリン
ジェイコブソン キャサリン
ジョシュア イーズ カレブ
ジョシュア イーズ カレブ
Original Assignee
ティルレイ，インコーポレイティド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ティルレイ，インコーポレイティド filed Critical ティルレイ，インコーポレイティド
Publication of JP2020514282A publication Critical patent/JP2020514282A/ja
Publication of JP2020514282A5 publication Critical patent/JP2020514282A5/ja
Priority to JP2022165695A priority Critical patent/JP2023001138A/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Biotechnology (AREA)
  • Botany (AREA)
  • Medical Informatics (AREA)
  • Microbiology (AREA)
  • Neurology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Pyrane Compounds (AREA)
JP2019534858A 2016-12-20 2017-12-20 新規カンナビノイド組成物および使用方法 Pending JP2020514282A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022165695A JP2023001138A (ja) 2016-12-20 2022-10-14 新規カンナビノイド組成物および使用方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662436861P 2016-12-20 2016-12-20
US62/436,861 2016-12-20
PCT/IB2017/001683 WO2018115962A1 (en) 2016-12-20 2017-12-20 Novel cannabinoid compositions and methods of treating pediatric epilepsy

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022165695A Division JP2023001138A (ja) 2016-12-20 2022-10-14 新規カンナビノイド組成物および使用方法

Publications (2)

Publication Number Publication Date
JP2020514282A true JP2020514282A (ja) 2020-05-21
JP2020514282A5 JP2020514282A5 (https=) 2021-02-04

Family

ID=61028091

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019534858A Pending JP2020514282A (ja) 2016-12-20 2017-12-20 新規カンナビノイド組成物および使用方法
JP2022165695A Pending JP2023001138A (ja) 2016-12-20 2022-10-14 新規カンナビノイド組成物および使用方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022165695A Pending JP2023001138A (ja) 2016-12-20 2022-10-14 新規カンナビノイド組成物および使用方法

Country Status (12)

Country Link
US (1) US20200215022A1 (https=)
EP (1) EP3558297A1 (https=)
JP (2) JP2020514282A (https=)
KR (1) KR20190099221A (https=)
AU (1) AU2017381587A1 (https=)
BR (1) BR112019012776A2 (https=)
CA (1) CA3046320A1 (https=)
CL (1) CL2019001668A1 (https=)
CO (1) CO2019006911A2 (https=)
MX (1) MX2019007496A (https=)
PE (1) PE20200338A1 (https=)
WO (1) WO2018115962A1 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
GB201806953D0 (en) 2018-04-27 2018-06-13 Gw Res Ltd Cannabidiol Preparations
IL261132A (en) * 2018-08-13 2018-11-04 Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd Formulated cannabis oil powder by nanoemulsifycation, methods of producing and uses thereof
GB2580653A (en) * 2019-01-21 2020-07-29 Gw Res Ltd Use of cannabinoids in the treatment of comorbidities associated with epilepsy
CA3130763A1 (en) 2019-02-25 2020-09-03 Ginkgo Bioworks, Inc. Biosynthesis of cannabinoids and cannabinoid precursors
US11759447B1 (en) 2019-06-26 2023-09-19 RCR BioPharma Compound and method for treating diseases and disorders
GB2598922A (en) 2020-09-18 2022-03-23 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2022232574A1 (en) 2021-04-29 2022-11-03 Tilray, Inc. Cannabidiol-dominant formulations, methods of manufacturing, and uses thereof
WO2023047308A1 (en) * 2021-09-22 2023-03-30 Avicanna Inc. Methods for reducing or eliminating incidence of seizures and sudden unexpected death in epilepsy
JP2025512495A (ja) 2022-04-12 2025-04-17 シャッケルフォード・ファーマ・インコーポレーテッド 発作性障害の治療

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512943A (ja) * 2001-02-14 2005-05-12 ジーダブリュー ファーマ リミテッド 医薬製剤
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2531282A (en) * 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
MX385464B (es) * 2014-12-12 2025-03-18 Ojai Energetics Pbc Composiciones microencapsuladas de cannabinoides
HK1244715A1 (zh) * 2015-03-02 2018-08-17 阿福金制药有限责任公司 用大麻素的局部区域神经影响性疗法
EP3253375B1 (en) * 2016-02-11 2019-04-10 Gelpell AG Oral solid cannabinoid formulations, methods for producing and using thereof

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005512943A (ja) * 2001-02-14 2005-05-12 ジーダブリュー ファーマ リミテッド 医薬製剤
WO2015193668A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabidiol in the treatment of epilepsy
WO2015193667A1 (en) * 2014-06-17 2015-12-23 Gw Pharma Limited Use of cannabinoids in the treatment of epilepsy

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
EPILEPSIA, vol. 55, no. 6, JPN6021037583, 2014, pages 783 - 786, ISSN: 0004957540 *
EPILEPSY & BEHAVIOR, vol. 41, JPN6021037581, 2014, pages 277 - 282, ISSN: 0004957541 *
SEIZURE, vol. 35, JPN6021037584, 2016, pages 41 - 44, ISSN: 0004957539 *

Also Published As

Publication number Publication date
MX2019007496A (es) 2019-10-30
WO2018115962A1 (en) 2018-06-28
CO2019006911A2 (es) 2019-08-30
EP3558297A1 (en) 2019-10-30
PE20200338A1 (es) 2020-02-14
AU2017381587A1 (en) 2019-06-20
CL2019001668A1 (es) 2019-09-06
JP2023001138A (ja) 2023-01-04
BR112019012776A2 (pt) 2019-12-10
CA3046320A1 (en) 2018-06-28
KR20190099221A (ko) 2019-08-26
US20200215022A1 (en) 2020-07-09

Similar Documents

Publication Publication Date Title
JP2020514282A (ja) 新規カンナビノイド組成物および使用方法
US20230364052A1 (en) Composition and method for treating autism
EP3215148B1 (en) Use of low dose of tetrahydrocannabinol for the treatment of cognitive decline in elderly patients
AU2019297198B2 (en) Composition and method for treating pain
CN101939017B (zh) 大麻素在与抗精神病药物组合中的用途
JP6334511B2 (ja) 新規方法
JP2021525709A (ja) 自閉症スペクトラム障害の治療のためのカンナビスベースの組成物
US20240050454A1 (en) Compositions and Methods For Treating Neurological Conditions
JP2019510060A (ja) 胃腸管の炎症性疾患の治療のためのカンナビノイドおよびカンナビスベースの組成物および方法
US20240024340A1 (en) Compositions and Methods For Treating Migraine
WO2020188568A1 (en) Methods and compositions for treating autism spectrum disorder and associated disorders
WO2020183455A1 (en) Cannabinoid combinations for treating low back pain
RS65144B1 (sr) Postupak za lečenje prader-vilijevog sindroma
KR20150119227A (ko) 라퀴니모드에 의한 다발성 경화증의 진행형 형태의 치료
KR20080021139A (ko) 편두통을 위한 드로나비놀 치료
AU2021390590B2 (en) Antiinflammatory compositions comprising cannabidiol, delta-9- tetrahydrocannabinol and linalool
Gupta et al. Valbenazine for the treatment of adults with tardive dyskinesia
WO2020188569A1 (en) Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
JP2023549173A (ja) 心理的苦痛の処置のためのカンナビジオールの使用
WO2023215338A1 (en) Compositions and methods for treating cluster headache
KR20260049238A (ko) 만성 요통, 만성 비특이적 요통, 골관절염 또는 기타 만성 근골격 통증 병태를 포함하는 만성 근골격 통증의 치료 및/또는 예방에 사용하기 위한 델타-9-테트라하이드로칸나비놀 및 테르펜을 포함하는 조성물
McGuire et al. How to navigate the cannabis labyrinth-medicinal and/or recreational: Part 1
WO2023215344A2 (en) Compositions and methods for treating cluster-tic syndrome
WO2023215342A1 (en) Compositions and methods for treating trigeminal neuralgia
Harshit Gupta et al. Valbenazine for the Treatment of Adults with Tardive Dyskinesia

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201221

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201221

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210921

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211005

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220104

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220405

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220614

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221014

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20221014

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20221018

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20221108

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20221214

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20221220

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230113

C211 Notice of termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C211

Effective date: 20230117